Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Liabilities: 2011-2025

Historic Total Liabilities for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $216.0 million.

  • Enanta Pharmaceuticals' Total Liabilities fell 12.84% to $216.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.0 million, marking a year-over-year decrease of 12.84%. This contributed to the annual value of $216.0 million for FY2025, which is 12.84% down from last year.
  • Enanta Pharmaceuticals' Total Liabilities amounted to $216.0 million in FY2025, which was down 12.84% from $247.8 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Total Liabilities registered a high of $247.8 million during FY2024, and its lowest value of $39.4 million during FY2021.
  • For the 3-year period, Enanta Pharmaceuticals' Total Liabilities averaged around $236.5 million, with its median value being $245.5 million (2023).
  • In the last 5 years, Enanta Pharmaceuticals' Total Liabilities soared by 354.06% in 2023 and then declined by 12.84% in 2025.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' Total Liabilities stood at $39.4 million in 2021, then soared by 37.38% to $54.1 million in 2022, then skyrocketed by 354.06% to $245.5 million in 2023, then increased by 0.94% to $247.8 million in 2024, then decreased by 12.84% to $216.0 million in 2025.